ARK Investment Management 13F: Adds $11M to RXRX Stake

ARK Investment Management has increased its position in Recursion Pharmaceuticals, Inc. (NasdaqGS: RXRX) by 2.9 million shares. This move raised its stake by 7.8% to a total of 40.2 million shares, valued at approximately $126.7 million, according to the latest 13F filing with the SEC for the reporting period ending recently.

What Changed in ARK Investment Management's Recursion Pharmaceuticals Position

The fund's recent activity shows a boost in confidence, with an addition of 2.9 million shares to its holdings in Recursion Pharmaceuticals. Prior to this increase, ARK Investment Management held about 37.3 million shares. The latest filing indicates a commitment to the biotechnology company's future prospects.

Other Institutional Activity in Recursion Pharmaceuticals

Several other funds have also adjusted their stakes in Recursion Pharmaceuticals. BlackRock, Inc. grew its holdings by 4.3 million shares, bringing its total to 43.2 million shares valued at $132.6 million. State Street Corp also increased its position, adding 3.2 million shares for a total of 28.5 million shares worth $87.5 million. Meanwhile, Baillie Gifford & Co slightly trimmed its stake by 99,565 shares, ending with 23.7 million shares valued at $72.7 million.

Recursion Pharmaceuticals, Inc. Stock Down 4.2%

Shares of Recursion Pharmaceuticals are trading around $3.15. The company has a market capitalization of $1.67 billion and a beta of 1.004, indicating moderate volatility. Its 52-week trading range is between $2.77 and $7.18. The stock's 50-day moving average is $3.33, and the 200-day moving average is $4.18, suggesting some recent downward pressure.

Recent Earnings

Recursion Pharmaceuticals reported revenue of $66.4 million, reflecting a decline of 56.1% year-over-year. The company has not been profitable, with a negative return on equity of 57.2%. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at Recursion Pharmaceuticals, Inc.

Recent insider transactions at Recursion Pharmaceuticals include planned sales by CEO Najat Khan, who sold 23,588 shares at an average price of $3.58 on June 5, 2026. Christopher Gibson sold 40,000 shares at $3.62 on the same day, also under a planned sale. Namandje Bumpus sold 4,386 shares at $3.54 on June 3, 2026, as part of a planned transaction.

Analysts Set New Price Targets

Analysts have maintained their ratings on Recursion Pharmaceuticals. On May 14, 2026, Morgan Stanley maintained a hold rating with a $5.5 price target. JP Morgan reiterated a buy rating with a $10 target on April 30, 2026. The consensus among analysts is a target price of $6.64, with a mix of hold and buy recommendations from seven analysts.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a biotech company based in Salt Lake City, Utah, focusing on drug discovery through technological innovations. The company is engaged in developing treatments for various conditions such as familial adenomatous polyposis and solid tumors. It collaborates with major pharmaceutical companies like Roche, Genentech, and Sanofi.

Bottom Line

ARK Investment Management's increased stake in Recursion Pharmaceuticals suggests confidence in the company's potential, although the backward-looking nature of 13F filings means the position may have changed since. Investors will be watching upcoming earnings and clinical trial developments closely. Recursion's focus on innovative drug discovery makes it a company of interest in the biotech sector.